| P/E (FY) | 31.5 | Sales (TTM) | $12.22B |
| Earnings (TTM) | $4.34B | ROE | 22.54% |
| Net Margin | 32.94% | ROIC | 27.95% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | 6.12% | Sales Growth 3Y | 10.35% |
Vertex Pharmaceuticals is a biotechnology company operating in the United States, Europe, and internationally, focused on serious diseases in specialty markets including cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia, and acute pain. Its cystic fibrosis medicines include TRIKAFTA/KAFTRIO, ALYFTREK, SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO. The company also develops CASGEVY for sickle cell disease and beta thalassemia, JOURNAVX for acute pain, and the VX-522 CFTR mRNA therapeutic.
| Market Cap | $122.67B | Trading Days | 6679 |
| 52W High | 531.86 |
| 52W Low | 362.50 |
| % Off High | −9.12% |
| YTD | 6.61% | 1Y | 3.19% |
| 3Y | 37.18% | 5Y | 141.21% |
| 10Y | 398.28% | Since incept. (ann.) | 13.00% |
Pharmaceuticals 100%
| Ann. Volatility (1Y) | 35.02% | Ann. Volatility (3Y) | 29.46% |
| Sharpe (1Y) | 0.32 | Sharpe (3Y) | 0.51 |
| Max Drawdown (1Y) | −22.39% | Max Drawdown (3Y) | −29.07% |
| Beta (3Y, vs SPY) | 0.14 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| BMY | BRISTOL MYERS SQUIBB CO | $128.85B | 18.2 |
| PFE | PFIZER INC | $143.34B | 18.5 |
| ABT | ABBOTT LABORATORIES | $188.12B | 29.0 |
| REGN | REGENERON PHARMACEUTICALS, INC. | $65.34B | 16.8 |
| MRK | Merck & Co., Inc. | $321.97B | 17.9 |
| TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | $40.45B | 28.7 |
| ALNY | ALNYLAM PHARMACEUTICALS, INC. | $38.01B | 123.0 |
| RPRX | Royalty Pharma plc | $33.40B | 33.2 |
| ZTS | Zoetis Inc. | $32.67B | 12.9 |
| ABBV | AbbVie Inc. | $465.20B | 111.6 |
| ONC | BeOne Medicines Ltd. | $472.90B | 1722.2 |
| ROIV | Roivant Sciences Ltd. | $23.64B | — |